9MR1
SARS-CoV-2 S2 monomer in complex with R125-61 Fab
Summary for 9MR1
| Entry DOI | 10.2210/pdb9mr1/pdb |
| EMDB information | 48548 |
| Descriptor | R125-61 Fab Heavy chain, R125-61 Fab Light chain, Spike protein S2, ... (4 entities in total) |
| Functional Keywords | sars-cov-2, spike, s2, covid, monoclonal antibody, complex, viral protein, viral protein-immune system complex, virus |
| Biological source | Homo sapiens (human) More |
| Total number of polymer chains | 3 |
| Total formula weight | 77744.30 |
| Authors | |
| Primary citation | Changrob, S.,Yasuhara, A.,Park, S.,Bangaru, S.,Li, L.,Troxell, C.A.,Halfmann, P.J.,Erickson, S.A.,Catanzaro, N.J.,Yuan, M.,Zhou, P.,Huang, M.,Wilbanks, G.D.,McGrath, J.J.C.,Singh, G.,Nelson, S.A.,Fu, Y.,Zheng, N.Y.,Carayannopoulos, S.M.,Dugan, H.L.,Shaw, D.G.,Stamper, C.T.,Madariaga, M.L.L.,Krammer, F.,Andrabi, R.,Burton, D.R.,Ward, A.B.,Wilson, I.A.,Kawaoka, Y.,Wilson, P.C. Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2. J.Exp.Med., 222:-, 2025 Cited by PubMed Abstract: The S2 subunit of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is highly conserved across coronavirus strains and therefore is a potential pan-coronavirus vaccine target. However, antibodies targeting this region are typically non-neutralizing. We report herein that S2-targeting antibodies from patients who recovered from SARS-CoV-2 infection bound only closely related sarbecovirus subgenus strains and, like most known S2 antibodies, none of these were neutralizing. In contrast, first-exposure, severe acutely infected COVID-19 patients predominantly induced back-boosted antibody-secreting cells imprinted against past common cold coronavirus strain OC43 that were cross-reactive to as many as five subgenera of betacoronavirus strains and gave rise to antibodies that were neutralizing and protective. The antibodies targeted two different sites: one defined by competition with stem helix antibodies, and the second to an underdescribed epitope at the apex of S2. These findings suggest that S2-targeted vaccines could strategically exploit controlled OC43 priming followed by SARS-CoV-2 boosting to enhance the breadth and quality of protective antibody responses. PubMed: 41066082DOI: 10.1084/jem.20251146 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.59 Å) |
Structure validation
Download full validation report
